Boston Advisors LLC increased its position in Colgate-Palmolive (NYSE:CL) by 91.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 186,314 shares of the company’s stock after purchasing an additional 88,761 shares during the quarter. Colgate-Palmolive makes up about 0.7% of Boston Advisors LLC’s investment portfolio, making the stock its 29th largest holding. Boston Advisors LLC’s holdings in Colgate-Palmolive were worth $12,770,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Advisor Partners LLC raised its stake in Colgate-Palmolive by 3.7% during the first quarter. Advisor Partners LLC now owns 12,991 shares of the company’s stock valued at $890,000 after buying an additional 464 shares during the last quarter. Brinker Capital Inc. bought a new stake in shares of Colgate-Palmolive in the 1st quarter worth $207,000. BB&T Corp increased its holdings in shares of Colgate-Palmolive by 1.2% in the 1st quarter. BB&T Corp now owns 274,086 shares of the company’s stock worth $18,786,000 after purchasing an additional 3,129 shares in the last quarter. Merriman Wealth Management LLC bought a new stake in shares of Colgate-Palmolive in the 1st quarter worth $205,000. Finally, Lantz Financial LLC bought a new stake in shares of Colgate-Palmolive in the 1st quarter worth $1,249,000. Institutional investors and hedge funds own 76.27% of the company’s stock.

Shares of CL opened at $69.01 on Wednesday. The company has a debt-to-equity ratio of 32.25, a current ratio of 1.14 and a quick ratio of 0.76. Colgate-Palmolive has a one year low of $57.41 and a one year high of $70.06. The firm has a market capitalization of $59.63 billion, a P/E ratio of 23.24, a PEG ratio of 4.55 and a beta of 0.79.

Colgate-Palmolive (NYSE:CL) last issued its quarterly earnings data on Friday, January 25th. The company reported $0.74 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Colgate-Palmolive had a return on equity of 25,268.29% and a net margin of 15.44%. The company had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.78 billion. During the same quarter in the previous year, the company posted $0.75 earnings per share. Colgate-Palmolive’s revenue was down 2.1% compared to the same quarter last year. Equities research analysts predict that Colgate-Palmolive will post 2.83 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Friday, April 19th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Wednesday, April 17th. This represents a $1.72 annualized dividend and a dividend yield of 2.49%. This is a positive change from Colgate-Palmolive’s previous quarterly dividend of $0.42. Colgate-Palmolive’s payout ratio is presently 57.91%.

In related news, Director John T. Cahill sold 5,780 shares of Colgate-Palmolive stock in a transaction on Thursday, January 31st. The stock was sold at an average price of $64.46, for a total value of $372,578.80. Following the completion of the sale, the director now owns 27,820 shares of the company’s stock, valued at $1,793,277.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Henning I. Jakobsen sold 969 shares of Colgate-Palmolive stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $66.39, for a total value of $64,331.91. Following the completion of the sale, the chief financial officer now directly owns 35,208 shares of the company’s stock, valued at approximately $2,337,459.12. The disclosure for this sale can be found here. Insiders sold 103,200 shares of company stock valued at $6,900,449 in the last ninety days. 1.14% of the stock is currently owned by corporate insiders.

A number of analysts have commented on the company. Zacks Investment Research lowered Colgate-Palmolive from a “buy” rating to a “sell” rating in a report on Monday, April 15th. Citigroup set a $68.00 target price on Colgate-Palmolive and gave the stock a “hold” rating in a report on Tuesday, March 19th. UBS Group lifted their target price on Colgate-Palmolive from $71.00 to $75.00 and gave the stock a “buy” rating in a report on Friday, March 29th. Macquarie set a $57.00 target price on Colgate-Palmolive and gave the stock a “hold” rating in a report on Tuesday, January 29th. Finally, Credit Suisse Group assumed coverage on Colgate-Palmolive in a report on Wednesday, March 6th. They issued an “underperform” rating for the company. Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $65.73.

ILLEGAL ACTIVITY NOTICE: “Colgate-Palmolive (CL) Shares Bought by Boston Advisors LLC” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/colgate-palmolive-cl-shares-bought-by-boston-advisors-llc/2983591.html.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.

Featured Article: Different Types of Derivatives

Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.